Evidence that a nigral gabaergic--cholinergic balance controls posture.
The intranigral injection of kainic acid (k.a.) (3.5 nM/s.n.) produced a lesion which resulted in a decreased muscarinic receptor binding capacity and in a decreased choline acetyl transferase (CAT) activity confined to the pars reticulata. The unilateral, intranigral injection of carbachol in the substantia nigra (s.n.) produced turning, ipsilateral to the injected side, of dose-related intensity, which was antagonized by scopolamine given either i.p. or intranigrally together with carbachol. The bilateral, intranigral injection of carbachol produced rigid catalepsy, highly resistant to apomorphine administration and antagonized by scopolamine. On the other hand, the catalepsy produced by intranigral picrotoxin was much more sensitive to apomorphine and was disrupted by systemic scopolamine administration. Intranigral scopolamine per se produced either contralateral turning or stereotyped movements consistently, when injected unilaterally or bilaterally, respectively. In addition, scopolamine injected bilaterally in the s.n. but not in the caudate nucleus (c.n.), at the concentration of 64 nM side, was able to antagonize the haloperidol-induced catalepsy and to prevent the tremors and the muscular rigidity produced by arecoline. This effect of scopolamine was surmountable with a higher dose of arecoline. Finally, intranigral muscimol (0.44 nM/s.n.) prevented the occurrence of the parkinsonian syndrome produced by systemic arecoline. It is concluded that the muscarinic receptors present in the s.n. pars reticulata play a role in the control of posture opposite to that of the nigral GABA receptors.
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001115:Arecoline / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D002217:Carbachol / Q000494:pharmacology; D002375:Catalepsy / Q000139:chemically induced; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D007608:Kainic Acid / Q000494:pharmacology; D008297:Male; D011187:Posture; D051381:Rats; D011950:Receptors, Cholinergic / Q000502:physiology*; D011976:Receptors, Muscarinic / Q000502:physiology*; D012601:Scopolamine / Q000494:pharmacology; D013239:Stereotyped Behavior; D013378:Substantia Nigra / Q000187:drug effects / Q000502:physiology*; D005680:gamma-Aminobutyric Acid / Q000502:physiology*
D011950:Receptors, Cholinergic; D011976:Receptors, Muscarinic; D001115:Arecoline; D005680:gamma-Aminobutyric Acid; D002217:Carbachol; D012601:Scopolamine; D002795:Choline O-Acetyltransferase; D006220:Haloperidol; D001058:Apomorphine; D007608:Kainic Acid